Expression and Clinical Signification of IL-10 and IL-17 in Endometrial Cancer

LI Lin, CHENG Chu, DUAN Rui-qi. et al

Abstract

To explore the expression of IL-10 and IL-17 in endometrial cancer and their relationships with tumor progression. Methods The sera levels of IL-10 and IL-17 were detected by enzyme-linked immune-sorbent assay in 15 benign hysterectomies and 15 endometrial cancers, the expressions of IL-10 and IL-17 in the tissue were measured by immunohistochemistry assay (SABC) with the evaluation of IOD value, clinic-pathological characteristics were retrieved and analyzed. Results Both sera expression and tissue IOD value of IL-10 were significantly higher in endometrial cancer than those in benign uterine, while no difference was found in IL-17 between the two groups. Sera IL-10 of ⅠB-Ⅱ stage, G2-G3, with myoinvasion, with vas tumor emboli was higher than that of ⅠA stage, G1, without myoinvasion, and without vas tumor emboli, while no difference was found among tissue types. Sera IL-17 of ⅠB-Ⅱ stage, with myoinvasion, with vas tumor emboli was lower than that of IA stage, without myoinvasion, and without vas tumor emboli, while no difference was found among tumor grades nor tissue types. Conclusion High expression of IL-10 may participate in the genesis and development of uterine endometrial cancer, while low expression of IL-17 may participate in its development.

 

Keywords: IL-10 IL-17, Endometrial cancer 

 

Full Text:

PDF


References


Colombo N. Preti E. Landoni F. et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol,2011;22(6):35-39.

Zou W. Immunosuppressive networks in the tumour environment and their therapeutic reles'ance. Nat Rev Cancer, 2005;5(4):263-274.

Strauss L. Bergmann C, Szczepanski M. et al. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta 1 mediates suppression in the tumor microenvironment. Clin Cancer Res, 2007; 13 ( 15): 4345-4354.

Korn T, Bettell IE. Oukka M. et al. IL-17 and Thl7 cells. Annu Rev Immunol,2009;27( 1); 185-517.

Maruyama T, Kono K, Mizukami Y. et al. Distribution of Till7 cells and FoxP3 ( + ) regulatory T cells in tumor- infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci,2010;101 (9); 1947-1954.

Hou F. Li Z, Ma D, et al. Distribution of Thl7 cells and Foxp3-expressing T cells in tumor-infiltrating lymphocytes in patients with uterine cervical cancer. Clin Chim Acta,2012;413 (23-24):1848-1854.

Zhang Y, Ma D. Tian Y. et al. The imbalance of Thl7/Treg in patients with uterine cervical cancer. Clin Chim Acta,2011; 412(11-12);894-900.

Yamagami W, Susumu N, Tanaka H. et al. Immunofluorescence-detected infiltration of CD4+ FOXP3 + regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int J Gynecol Cancer, 2011; 21 ( 9): 1628- 1634.

Candido EB, Silva LM, Carvalho AT, et al. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer. Reprod Sci,2013;20(7):828-837.

Kryczek I, Banerjee M. Cheng P, et al. Phenotype, distribution, generation, and functional and clinical reles'ance of Th 17 cells in the human tumor environments. Blood. 2009; 114(6);1141-1149.


Refbacks

  • There are currently no refbacks.